Cellares and TScan Therapeutics agreed to evaluate automated manufacturing for TSC-101, TScan’s TCR-T therapy candidate intended for patients with AML and MDS undergoing allogeneic hematopoietic cell transplantation. The collaboration will assess automated clinical manufacturing using Cellares’ Cell Shuttle platform and Cell Q automated quality control system. The program is aimed at making cell therapy production more scalable and consistent by reducing process variability and manual labor. TSC-101 is designed to address measurable residual disease and prevent relapse after transplant. The companies framed the evaluation as part of commercial readiness ahead of a pivotal trial expected to start in the second quarter of 2026. For TScan, automation may help address capacity and cost constraints as demand grows beyond single-site manufacturing. Operationally, the deal signals that the next wave of cell therapy competition may be less about just the biology and more about execution reliability at scale.